Literature DB >> 19614729

Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma.

Doina Ivan1, Victor G Prieto, Bita Esmaeli, Ignacio I Wistuba, Ximing Tang, Alexander J F Lazar.   

Abstract

Sebaceous carcinoma has a predominant periocular origin but can also be extraocular. These two groups have distinct clinical courses. Insight into the molecular determinants of tumorigenesis and metastasis is limited. There is no effective treatment for metastatic sebaceous carcinoma. Epidermal growth factor receptor (EGFR) is implicated in tumorigenesis and can be a therapeutic target in certain settings. We evaluated EGFR levels by immunohistochemistry (IHC), comparing its expression between periocular and extraocular tumors and assessed EGFR mutation status. IHC was performed in 36 cases: 19 periocular and 17 extraocular (10 associated with Muir-Torre syndrome-MTS). EGFR IHC was scored for percentage of positive cells (< 5%, 5-25%, 26-50%, > 50%) and intensity (+1 = low , +2 = moderate , +3 = high ). Extraocular carcinomas showed markedly increased levels of EGFR when compared to periocular carcinoma cases, both in terms of distribution (88% were > 25% of tumor cells vs. 16%) and intensity (77% were 2+ or 3+ vs. 21%) (p < 0.001). Among extraocular cases, there was significantly lower EGFR expression in MTS-related cases (p < 0.05). No EGFR mutations were identified. Our results underscore the divergent mechanisms underlying the tumorigenesis of periocular and extraocular sebaceous carcinoma and suggest an association between aggressive behavior and increased EGFR expression in extraocular sebaceous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614729     DOI: 10.1111/j.1600-0560.2009.01316.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  4 in total

1.  Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.

Authors:  Min Joung Lee; Namju Kim; Ho-Kyung Choung; Ji-Young Choe; Sang In Khwarg; Ji Eun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-04       Impact factor: 4.553

Review 2.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.

Authors:  Vivian T Yin; Helen Merritt; Bita Esmaeli
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

Review 3.  Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.

Authors:  Vivian T Yin; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Mar-Apr       Impact factor: 1.746

4.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.